Pacira Biosciences Inc
pacira.comPacira BioSciences (NASDAQ: PCRX) is a specialty pharmaceutical company that develops and commercializes non-opioid pain therapies. Revenue comes from direct product sales of three commercialized treatments: EXPAREL (bupivacaine liposome injectable suspension), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), and iovera, a handheld cryotherapy device. EXPAREL, the flagship product, generated net product sales of $575.1 million in FY2025, representing 79% of total revenues. ZILRETTA is the first and only extended-release single-shot corticosteroid intra-articular injection for osteoarthritis knee pain. The company is incorporated in Delaware and operates through a California subsidiary, Pacira Pharmaceuticals, Inc., acquired from SkyePharma Holdings in March 2007. The pipeline includes PCRX-201, a gene therapy in Phase 2 clinical development for osteoarthritis of the knee. The company has incurred significant losses since inception and does not pay dividends, per the FY2025 10-K filed February 26, 2026.
Products & Services
EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis knee pain; iovera (handheld cryotherapy device for drug-free nerve-targeted pain control); PCRX-201 (enekinragene inzadenovec), a gene therapy in Phase 2 development for osteoarthritis of the knee.
Revenue Model
Transactional product sales of three commercialized non-opioid pain treatments. EXPAREL accounted for 79% of total revenues in FY2025 ($575.1 million), 78% in FY2024 ($549.0 million), and 80% in FY2023 ($538.1 million).
Customers & Markets
Hospital and surgical settings for postsurgical pain management; orthopedic and pain management practices for osteoarthritis knee pain. End markets include acute surgical care and chronic joint pain treatment.
Geographic Exposure
Primary operations in the United States. No material geographic revenue breakdown provided in the excerpts.
Loading...
